<?xml version="1.0" encoding="us-ascii"?><InstanceReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><Version>2.4.0.8</Version><ReportLongName>006 - Disclosure - Note 1 - Organization and Basis of Presentation</ReportLongName><DisplayLabelColumn>true</DisplayLabelColumn><ShowElementNames>false</ShowElementNames><RoundingOption /><HasEmbeddedReports>false</HasEmbeddedReports><Columns><Column FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><CurrencyCode /><FootnoteIndexer /><hasSegments>false</hasSegments><hasScenarios>false</hasScenarios><MCU><KeyName /><CurrencySymbol /><contextRef><ContextID>c4_From1Jan2013To30Jun2013</ContextID><EntitySchema>http://www.sec.gov/CIK</EntitySchema><EntityValue>0001347022</EntityValue><PeriodDisplayName /><PeriodType>duration</PeriodType><PeriodStartDate>2013-01-01T00:00:00</PeriodStartDate><PeriodEndDate>2013-06-30T00:00:00</PeriodEndDate><Segments /><Scenarios /></contextRef><UPS /><CurrencyCode /><OriginalCurrencyCode /></MCU><CurrencySymbol /><Labels><Label Key="CalendarSupplement" Id="0" Label="6 Months Ended" /><Label Key="Calendar" Id="1" Label="Jun. 30, 2013" /></Labels></Column></Columns><Rows><Row FlagID="0"><Id>1</Id><IsAbstractGroupTitle>true</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>1</Level><ElementName>us-gaap_DisclosureTextBlockAbstract</ElementName><ElementPrefix>us-gaap_</ElementPrefix><IsBaseElement>true</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText /><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>xbrli:stringItemType</ElementDataType><SimpleDataType>string</SimpleDataType><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>Disclosure Text Block [Abstract]</Label></Row><Row FlagID="0"><Id>2</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>2</Level><ElementName>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</ElementName><ElementPrefix>us-gaap_</ElementPrefix><IsBaseElement>true</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><PreferredLabelRole>terseLabel</PreferredLabelRole><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="c4_From1Jan2013To30Jun2013" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText>&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1788"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;&lt;b&gt;1.&amp;#160;&amp;#160;&amp;#160;Organization

      and Basis of Presentation&lt;/b&gt;&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1790"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;PositiveID,

      through its wholly owned subsidiary MicroFluidic Systems

      (&amp;#8220;MFS&amp;#8221;) (collectively, the &amp;#8220;Company&amp;#8221;

      or &amp;#8220;PositiveID&amp;#8221;) , develops molecular diagnostic

      systems for bio-threat detection, for rapid diagnostic

      testing, and also develops assays to detect a range of

      biological threats. The Company&amp;#8217;s M-BAND (Microfluidic

      Bio-agent Autonomous Networked Detector) system is an

      airborne bio-threat detection system developed for the

      homeland defense industry, to detect biological weapons of

      mass destruction.&amp;#160;&amp;#160;The Company is also developing

      automated pathogen detection systems Firefly Dx (handheld)

      and Dragonfly (desktop) for rapid diagnostics, both for point

      of need and clinical applications.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1792"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;PositiveID

      is a Delaware corporation formed in 2001. The Company

      commenced operations in 2002 as VeriChip Corporation. In

      2007, the Company completed an initial public offering of its

      common stock.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1794"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;In

      July 2008, the Company completed the sale of all of the

      outstanding capital stock of its subsidiary, Xmark

      Corporation (&amp;#8220;Xmark&amp;#8221;), which at the time was

      principally all of the Company&amp;#8217;s operations to Stanley

      Canada Corporation (&amp;#8220;Stanley&amp;#8221;), a wholly-owned

      subsidiary of Stanley Black and Decker. The sale transaction

      was closed for $47.9&amp;#160;million in cash, which consisted of

      the $45&amp;#160;million purchase price plus a balance sheet

      adjustment of approximately $2.9&amp;#160;million, which was

      adjusted to $2.8&amp;#160;million at settlement of the escrow.

      Under the terms of the stock purchase agreement,

      $43.4&amp;#160;million of the proceeds were paid at closing and

      $4.4&amp;#160;million was released from escrow in July&amp;#160;2009.

      As a result, the Company recorded a gain on the sale of Xmark

      of $6.2&amp;#160;million, with $4.5&amp;#160;million of that gain

      deferred until the escrow was settled in 2009.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1796"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;Following

      the completion of the sale, the Company retired all of its

      outstanding debt for a combined payment of $13.5&amp;#160;million

      and settled all contractual payments to Xmark&amp;#8217;s and the

      Company&amp;#8217;s officers and management for

      $9.1&amp;#160;million. In August 2008, the Company paid a special

      dividend to its stockholders of $15.8&amp;#160;million.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1798"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;In

      November 2008, the Company entered into an Asset Purchase

      Agreement (&amp;#8220;APA&amp;#8221;) with Digital Angel Corporation

      and Destron Fearing Corporation, a wholly-owned subsidiary of

      Digital Angel Corporation, which collectively is referred to

      as &amp;#8220;Digital Angel.&amp;#8221; The terms of the APA included

      the Company&amp;#8217;s purchase of patents related to an

      embedded bio-sensor system for use in humans, and the

      assignment of any rights of Digital Angel under a development

      agreement associated with the development of an implantable

      glucose sensing microchip. The Company also received

      covenants from Digital Angel Corporation and Destron Fearing

      that will permit the use of intellectual property of Digital

      Angel related to the Company&amp;#8217;s health care business

      without payment of ongoing royalties, as well as inventory

      and a limited period of technology support by Digital Angel.

      The Company paid Digital Angel $500,000 at the closing of the

      APA, which was recorded in the financials as research and

      development expense.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1801"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;In

      September 2009, the Company, VeriChip Acquisition Corp., a

      Delaware corporation and wholly-owned subsidiary of the

      Company (the &amp;#8220;Acquisition Subsidiary&amp;#8221;), and Steel

      Vault Corporation, a Delaware corporation (&amp;#8220;Steel

      Vault&amp;#8221;), signed an Agreement and Plan of Reorganization

      (the &amp;#8220;Merger Agreement&amp;#8221;), dated September&amp;#160;4,

      2009, as amended, pursuant to which the Acquisition

      Subsidiary was merged with and into Steel Vault on

      November&amp;#160;10, 2009, with Steel Vault surviving and

      becoming a wholly-owned subsidiary of the Company (the

      &amp;#8220;Merger&amp;#8221;). Upon the consummation of the Merger,

      all outstanding shares, options and warrants of Steel

      Vault&amp;#8217;s common stock were converted into approximately

      0.2&amp;#160;million shares of common stock, 0.1&amp;#160;million

      options, and 18,200 warrants of the Company. At the closing

      of the Merger, the Company changed its name to PositiveID

      Corporation.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1803"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;In

      February&amp;#160;2010, the Company acquired the assets of Easy

      Check Medical Diagnostics, LLC (&amp;#8220;Easy Check&amp;#8221;),

      which included the glucose breath analysis system and the

      &lt;i&gt;iglucose&amp;#160;&lt;/i&gt;wireless communication system. The

      Company issued 12,000 shares of common stock in February

      2010, with a fair value of $351,000, as consideration for the

      purchase. &amp;#160;The purchase agreement also included certain

      contingent payments and cash royalties based on future

      revenues.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1805"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;In

      May 2011, the Company entered into a Stock Purchase Agreement

      to acquire MFS, pursuant to which MFS became a wholly-owned

      subsidiary of the Company.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1807"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;Beginning

      with the acquisition of MFS, the Company began a process to

      focus its operations on molecular diagnostics and

      detection.&amp;#160;&amp;#160;Since acquiring MFS, the Company has

      (i) sold substantially all of the assets of

      NationalCreditReport.com in 2011, which it had acquired in

      the merger that formed PositiveID in 2009, (ii) sold its

      VeriChip and HealthLink (personal health record) businesses

      in 2012, and (iii) entered into an exclusive license for its

      &lt;i&gt;iglucose&lt;/i&gt; technology in 2013.&amp;#160;&amp;#160;The Company

      will continue to seek either strategic partners or acquirers

      for its GlucoChip (glucose sensing microchip) and its glucose

      breath detection system.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1809"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;&lt;b&gt;Authorized

      Common Stock (Reverse Stock Split)&lt;/b&gt;&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1811"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;As

      of June 30, 2013, the Company was authorized to issue 470

      million shares of common stock.&amp;#160;&amp;#160;On April 18, 2013,

      the Company&amp;#8217;s stockholders approved a reverse stock

      split within a range between 1-for-10 to 1-for-25. On that

      same date, the Company&amp;#8217;s Board of Directors approved a

      reverse stock split in the ratio of 1-for- 25 and the Company

      filed a Certificate of Amendment to its Second Amended and

      Restated Certificate of Incorporation, as amended, with the

      Secretary of State of the State of Delaware to effect the

      reverse stock split. The reverse split only affected

      outstanding common stock and the number of authorized shares

      was not adjusted. On April 23, 2013, the reverse stock split

      became effective.&amp;#160;&amp;#160;All share amounts in our

      historical financial statements have been adjusted to reflect

      the 1-for-25 reverse stock split.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1813"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;&lt;b&gt;Going

      Concern&lt;/b&gt;&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1815"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;The

      Company&amp;#8217;s consolidated financial statements have been

      prepared assuming the Company will continue as a going

      concern. As of June 30, 2013, the Company had a working

      capital deficiency of approximately $6.4 million and an

      accumulated deficit of $119.2 million, compared to a working

      capital deficiency of $4.6 million and an&amp;#160;accumulated

      deficit of approximately $111.3 million as of December 31,

      2012.&amp;#160;&amp;#160;The Company has incurred operating losses

      since its inception, and has not generated revenue from

      continuing operations since 2009. The current operating

      losses are the result of research and development expenses

      and selling, general and administrative expenses. The Company

      expects its operating losses to continue through at least

      2013. These conditions raise substantial doubt about the

      Company&amp;#8217;s ability to continue as a going

      concern.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1817"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;The

      Company&amp;#8217;s ability to continue as a going concern is

      dependent upon its ability to obtain financing to fund the

      continued development of its products and to support working

      capital requirements.&amp;#160;&amp;#160;Until the Company is able to

      achieve operating profits, the Company will continue to seek

      to access the capital markets. &amp;#160;In 2012 and 2011, the

      Company raised approximately $7.4 million from the issuance

      of convertible preferred stock, common stock under an equity

      line financing, and convertible debt.&amp;#160;&amp;#160;During the

      six months ended June 30, 2013, the Company has raised

      approximately $0.8 million, net of $0.3 million principal

      payment, from a debenture, convertible notes, preferred stock

      conversions, and through its equity line financings (See Note

      4).&amp;#160;&amp;#160;Additionally, in March and April 2013 the

      Company received $1,500,000 in two equal installments, under

      its license agreement with The Boeing Company (see Note

      9).&amp;#160;&amp;#160;During 2013, the Company will need to raise

      additional capital in order to execute its business

      plan.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;&lt;p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt; MARGIN: 0pt" id="PARA1819"&gt;

      &lt;font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"&gt;These

      conditions raise substantial doubt about the Company&amp;#8217;s

      ability to continue as a going concern. The Company intends

      to continue to access capital to provide funds to meet its

      working capital requirements for the near-term future. In

      addition and if necessary, the Company could reduce and/or

      delay certain discretionary research, development and related

      activities and costs. However, there can be no assurances

      that the Company will be able to negotiate additional sources

      of equity or credit for its long term capital needs. The

      Company&amp;#8217;s inability to have continuous access to such

      financing at reasonable costs could materially and adversely

      impact its financial condition, results of operations and

      cash flows, and result in significant dilution to the

      Company&amp;#8217;s existing stockholders. The Company&amp;#8217;s

      consolidated financial statements do not include any

      adjustments relating recoverability of assets and

      classifications of assets and liabilities that might be

      necessary should the Company be unable to continue as a going

      concern.&lt;/font&gt;

    &lt;/p&gt;&lt;br/&gt;</NonNumbericText><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>nonnum:textBlockItemType</ElementDataType><SimpleDataType>na</SimpleDataType><ElementDefenition>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</ElementDefenition><ElementReferences>No definition available.</ElementReferences><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>Business Description and Basis of Presentation [Text Block]</Label></Row></Rows><Footnotes /><IsEquityReport>false</IsEquityReport><ReportName>Note 1 - Organization and Basis of Presentation</ReportName><MonetaryRoundingLevel>UnKnown</MonetaryRoundingLevel><SharesRoundingLevel>UnKnown</SharesRoundingLevel><PerShareRoundingLevel>UnKnown</PerShareRoundingLevel><ExchangeRateRoundingLevel>UnKnown</ExchangeRateRoundingLevel><HasCustomUnits>true</HasCustomUnits><IsEmbedReport>false</IsEmbedReport><IsMultiCurrency>false</IsMultiCurrency><ReportType>Sheet</ReportType><RoleURI>http://positiveidcorp.com/role/Note1OrganizationandBasisofPresentation</RoleURI><NumberOfCols>1</NumberOfCols><NumberOfRows>2</NumberOfRows></InstanceReport>
